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In situ click chemistry: from small molecule discovery
to synthetic antibodies
Steven W. Millward,*a Heather D. Agnew,b Bert Lai,b Su Seong Lee,c Jaehong Lim,c
Arundhati Nag,d Suresh Pitram,b Rosemary Rohdeb and James R. Heathd
Advances in the fields of proteomics, molecular imaging, and therapeutics are closely linked to the availability
of aﬃnity reagents that selectively recognize their biological targets. Here we present a review of Iterative
Peptide In Situ Click Chemistry (IPISC), a novel screening technology for designing peptide multiligands with
high aﬃnity and specificity. This technology builds upon in situ click chemistry, a kinetic target-guided
synthesis approach where the protein target catalyzes the conjugation of two small molecules, typically
through the azide–alkyne Huisgen cycloaddition. Integrating this methodology with solid phase peptide
libraries enables the assembly of linear and branched peptide multiligands we refer to as Protein Catalyzed
Capture Agents (PCC Agents). The resulting structures can be thought of as analogous to the antigen
recognition site of antibodies and serve as antibody replacements in biochemical and cell-based applications.
In this review, we discuss the recent progress in ligand design through IPISC and related approaches, focusing
on the improvements in affinity and specificity as multiligands are assembled by target-catalyzed peptide
conjugation. We compare the IPISC process to small molecule in situ click chemistry with particular emphasis
on the advantages and technical challenges of constructing antibody-like PCC Agents.
Insight, innovation, integration
Ligands for high-specificity protein recognition are of considerable interest to
the biomedical community. This review provides a critical analysis of the
emerging field of Iterative Peptide In Situ Click Chemistry (IPISC) as a means
of developing highly selective ligands that bind to proteins with antibody-like
aﬃnity. In situ click chemistry is a target-guided synthesis approach where the
target protein is used as a scaﬀold upon which binding ligands are covalently
assembled by the azide–alkyne cycloaddition. Drawing inspiration from the
antigen-binding site of monoclonal antibodies, IPISC has the potential to
direct the assembly of artificial multi-peptide structures that recognize
protein surfaces with high-aﬃnity and specificity while retaining the stability
and chemical accessibility of synthetic compounds.
Introduction
Molecular recognition underlies all aspects of biology and is a
critical component of therapeutic design, molecular imaging, and
molecular diagnostics. The simplicity and robustness of nucleic acid
recognition though specific base pairing has enabled tremendous
technological advances in genomics and transcriptomics. A simi-
larly deep understanding of protein recognition has yet to emerge
despite considerable study. As a result, molecules developed for
specific protein recognition are usually identified through combi-
natorial screening processes, rather than through rational design.
Antibodies are the primary molecular tool for protein recogni-
tion, and find almost universal use in the biomedical community
for basic research, immunohistochemistry, diagnostic imaging,
and therapeutics. A key feature of antibodies is that they can often
be developed to exhibit high specificity for their target protein
antigen (although high specificity is not guaranteed1). How-
ever, they are prone to proteolytic, chemical, and thermal
degradation, which can limit their utility in non-laboratory
diagnostic environments. In addition, as biological com-
pounds, they are subject to batch-to-batch variability and
chemical modifications with dyes and aﬃnity tags can
detrimentally influence their properties. While antibodies have
found extensive use as therapeutics against extracellular pro-
tein targets, their utility in imaging applications can be
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compromised by long serum half-lives, leading to increased
background signal in all perfused tissue.
These shortcomings have prompted the development of
numerous chemical and biological display technologies for
designing ‘‘antibody-like’’ ligands.6 The goal is typically to
optimize desirable features such as reduced size, increased
stability, and ease of synthesis and labeling while achieving
antibody-like aﬃnity and specificity. These approaches include
aptamer technology,8 phage display,9 ribosome display,10
mRNA display,11 yeast display,12 and one-bead-one-compound
(OBOC) solid phase libraries.13 These techniques typically yield
linear or cyclic biopolymer ligands that bind to a single site, or
‘‘hot spot’’, on the surface of the protein target with high
aﬃnity. We review here the recently developed technique of
Iterative Peptide In Situ Click Chemistry (IPISC) for producing
protein capture agents. This technique draws from the above-
mentioned methodologies, but with a few critical diﬀerences
which are described below. The advantages are briefly listed
here. First, the protein target itself provides a highly selective
catalytic scaﬀold for assembling its own capture agent.
Through the application of novel screening approaches, the
resultant capture agent can be developed to exhibit high
selectivity for the target. Because of the protein-catalyzed
process, we have named these types of ligands Protein
Catalyzed Capture Agents, or PCC Agents. Second, PCC Agents
are assembled stepwise from comprehensive, chemically
synthesized OBOC libraries allowing stability-enhancing func-
tionalities (e.g. unnatural amino acids) to be incorporated at
the start, biasing the final products toward bio-stability. Third,
the approach permits the development of a wide variety of
capture agent architectures – linear, branched, cyclic or combi-
nations thereof, opening a regime of chemical space that is not
easily accessible with alternative approaches. Finally, PCC
Agents are defined chemical structures that can be scaled up
by automated chemical synthesis, avoiding the problem of
batch-to-batch reproducibility.
This review will discuss the use of Iterative Peptide In Situ
Click Chemistry to create minimized protein-binding surfaces
through the templated assembly of unique peptide sequences.
We will begin by touching upon the enabling technology of
small molecule in situ click chemistry (SISC), which provided
the initial foundation for IPISC. We will then consider the
architecture of the antigen-binding site of antibodies as a
model for protein recognition and biological inspiration for
IPISC. Finally, we will review the recent developments in IPISC
and related topics, comparing the two in situ click methodologies
and discussing the advantages and challenges of designing
multi-peptide PCC Agents.
Small molecule in situ click chemistry (SISC)
Small molecule in situ click chemistry (SISC) was originally
described by Sharpless and co-workers in 2002 to design potent
small molecule inhibitors of acetylcholinesterase (AChE).14
The principle behind this methodology is that the thermo-
dynamically favorable 1,3-dipolar Huisgen cycloaddition reac-
tion can be catalyzed in the absence of metal catalyst provided
that the two reactants are brought into close proximity in the
correct spatial orientation by a protein target (Fig. 1). Thus, for
SISC, a known inhibitor is split into two molecules, one
presenting an azide, and one presenting an acetylene group.
One or both of those halves is expanded into a library, and
the enzyme provides the scaﬀold for coupling those library
elements together. Only those elements that are mutually
compatible with the protein scaﬀold are clicked together. The
resulting triazole-linked compound will have a binding energy
as high as the sum of the free energies of the two reactants.15
Acetylcholinesterase was chosen as the target because of its
deep, well-characterized binding pocket which was known to
have two independent binding sites. The most potent of the
final compounds had a dissociation constant of less than 40 fM
against eel acetylcholinesterase representing almost the full
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sum of the component ligand binding energies. Highly potent
inhibitors of nicotinic acetylcholine receptor,16 carbonic anhydrase
II (CA II),17 HIV-1 protease,18 and bacterial chitinases19 have also
been discovered by these methods. For additional discussion of
this methodology, we refer the reader to a recent review of small
molecule in situ click chemistry.20
SISC is well suited when there exists a known inhibitor
structure that can be deconstructed into two or more independent
chemical functionalities. The small molecules that are built for
SISC represent a small, focused sampling of chemical space and
their design draws from knowledge of the original inhibitor and
the structure of the binding pocket. In most cases, it is the linker
length, rigidity, and composition being optimized by the in situ
screen, eﬀectively determining the optimal spatial orientation
between independent ligands. This is a powerful molecular design
feature, which has been employed to optimize the orientation of
larger peptide functionalities in Iterative Peptide In Situ Click
Chemistry. The rationale for this approach is provided, in part, by
the structure of the antigen-binding site used by monoclonal
antibodies.
Biological insight: the structural basis of
antibody–protein interactions
Antibodies recognize a wide range of ligands and surfaces
including nucleic acids,21 peptides,22 proteins,23 small mole-
cules,24 complex carbohydrates,25 lipids,26 inorganic surfaces,27
and pathogen surfaces.28 The adaptability of antibodies to
these disparate structures and chemistries lies in the surface
available for antigen recognition. The antigen binding site is
composed of six peptide loops, three from the heavy chain and
three from the light chain, forming a binding surface of
approximately 1400–1900 Å2 for protein targets.29 The amino
acid sequence of each loop is determined by the outcome of
VDJ recombination at the genetic level, resulting in a diverse
repertoire of surfaces with each loop contributing to the
chemistry and shape of the antigen recognition surface. How-
ever, not all six loops contribute equally to the aﬃnity and
specificity of the final interaction. The CDR-H3 loop on the
heavy chain is the most variable of the six, with a typical length
ranging from 10 to 22 amino acids30 and significantly higher
sequence diversity relative to the other five loops.31 This
sequence variability translates to increased conformational
variability across known antibody structures relative to the
other loops that define the binding surface.32 The CDR-H3 has
been shown inmany cases to define the specificity of the antibody–
antigen recognition with the other loops contributing stabilizing
interactions to increase aﬃnity and define the shape of the binding
site.31a In one report, the CDR3 loop alone was suﬃcient for low-
nanomolar binding of a camel single-domain antibody to carbonic
anhydrase.33 This phenomenon has been exploited to design
peptide ligands based on the CDR-H3 loop sequence to bind the
target antigen with high nanomolar aﬃnity.34
Crystal structures of antibodies and Fab fragments bound to
their cognate protein antigens reveal a diverse repertoire of
antigen-binding site architectures. In some cases, only a subset
of the six CDR loops are utilized in the high-aﬃnity antigen
recognition surface (Fig. 2). For example, antibody binding of
HIV p24 protein, Lysozyme, and VEGF, is mediated mainly
through the CDR-H3, CDR-L3, CDR-H1, and CDR-L3 loops, with
the CDR-H3 loop contributing significant binding interactions
in all three structures.
These observations suggest (1) 2–4 peptides in the proper
spatial arrangement can potentially recognize folded protein
antigens with high aﬃnity and specificity and (2) a single loop
can provide the majority of the interactions to mediate the
binding event. While existing library display methodologies can
determine the optimal sequence of the individual peptides,
their ideal relative orientation to one another, particularly in
a non-linear configuration, can be challenging to optimize. In situ
click chemistry, in combination with one-bead-one-compound
library technology, can provide the spatial information to assemble
a multi-peptide ligand with the aﬃnity and specificity of a mono-
clonal antibody.
PCC Agents through Iterative Peptide In Situ
Click Chemistry (IPISC)
The application of in situ click chemistry to the design of
multimeric PCC Agent peptide ligands was first demonstrated
by Agnew and co-workers in 2009,3 who developed a triligand
capture agent against bovine carbonic anhydrase II (bCAII).
PCC Agent development through IPISC proceeds stepwise,
beginning with a 11, or anchor ligand. That anchor ligand is
then used in an in situ screen to identify a 21 ligand. The 11 and
21 ligands are clicked together to form a biligand. The biligand
can be converted into an anchor for use in an in situ screen to
identify a 31 ligand, from which a triligand is formed, and so
on. A generalized schematic of Iterative Peptide In Situ Click
Chemistry shown in Fig. 3.
For the development of the bCAII PCC Agent, the 11 ligand
was identified through a standard OBOC target screen for
protein binding. The OBOC library was a random hexameric
library appended with D-propargylglycine. The library was com-
prised of D-amino acids to yield protease resistance and
improved bio-stability. Hit elements were selected for binding
to bCAII via a two-generation screen. The consensus anchor
ligand exhibited a weak aﬃnity (KD B 500 mM) against bCAII.
The anchor compound was then incubated with bCAII and a
Fig. 1 Schematic of small molecule in situ click chemistry (SISC). An azide-bearing
compound (blue) is brought into close proximity to an acetylene-bearing
compound (red) within the active site of a protein (yellow). Proximity and
orientation drive 1,2,3-triazole formation and conjugation of the two
compounds.
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second D-amino acid peptide library bearing azido-amino acids
of variable side-chain length. After two screens, a consensus 21
peptide was identified and conjugated to the anchor peptide by
the copper-catalyzed azide–alkyne cycloaddition (CuAAC) to
yield a biligand with significantly improved aﬃnity (KD =
3 mM). The process was repeated to generate a high aﬃnity
triligand (KD B 45 nM) that could function as a drop-in anti-
body replacement in immunoblotting experiments. Impor-
tantly, the triligand was formed on-bead only in the presence
of bCAII or human carbonic anhydrase II (hCAII) but not in the
presence of the unrelated proteins BSA or transferrin.
The architectural flexibility aﬀorded by IPISC is illustrated in
the structures, shown in Fig. 4, of four of the PCC Agent
triligands we have developed over the past couple of years.
These structures are color-coded so that the 11, 21, and 31
ligands are red, black, and blue, respectively, and each triligand
exhibits a mid- to low nM aﬃnity for their cognate proteins.
Fig. 4a is the linear anti-bCAII triligand discussed above, while
Fig. 4b is a branched variant on that structure, in which a
D-tryptophan at the 3-position in the 6-mer 21 ligand is replaced
with an azide-containing amino acid for the development of the
triligand branch. Fig. 4c is an anti-PSA PCC Agent triligand that
utilizes a cyclic peptide from the literature35 as the initial 11
ligand and anchor. Note that the triazole linkage connecting
the 21 and 31 ligands is a 1,5-triazole, as compared to the
1,4-triazoles that bridge all of the other ligands. The in situ click
reaction can generate either isoform and, if both variants are
tested, there can be a preference for one or the other, depending
on the flexibility of the linkage connecting the ligands. The
branched triligand shown in Fig. 4d is discussed below.
In 2011, Millward and co-workers applied this technique to
design a triligand capture agent with mid-nanomolar aﬃnity
for Protein Kinase B (Akt1).5 The resulting branched triligand
was found to inhibit the catalytic activity of Akt1 without
directly binding to the ATP or peptide substrate pockets,
suggesting an allosteric mode of inhibition. The triligand
immunoprecipitated Akt from OVCAR3 ovarian cancer cell lysates
and a fluorescent variant was used to image membrane-localized
Akt in cell culture after stimulation with insulin and EGF. In
both cases, the triligand compared favorably with commercial
monoclonal antibodies, particularly in immunoprecipitation
experiments where the eﬃciency of the antibody was found to
be very poor.
An innovation of this work was the use of ‘‘product screens’’
to select hit beads not on the basis of target binding (the
standard screening approach), but on the basis of on-bead
formation of the triazole linkage between the bead-immobilized
peptide and the soluble anchor peptide in the presence of the
protein target. For product screens, the soluble biotinylated
anchor peptide is incubated with the on-bead library in the
presence of the target biomolecule, and the beads are then
probed for the presence of biotin. Only the beads whose
sequences participate in the in situ click reaction will have a
covalently-linked biotin functionality. When carried out in the
absence of a target screen, the product screen resulted in modest
aﬃnity gains but significant gain in selectivity for Akt over the
GSK3b, the primary oﬀ-target binding interaction, implying that
the product screen can serve as a selectivity screen. It also served
as a powerful approach to removing false-positive hits, which
can account for 90% of the hit beads in the target screen. The
authors went on to use the principle of the product screen to
quantitate the eﬃciency of the on-bead in situ click reaction
Fig. 3 Generalized Schematic of Iterative Peptide In Situ Click Chemistry (IPISC).
An anchor peptide (black circles) is selected for binding to a site on the protein
surface (yellow) from a one-bead-one-compound peptide library (grey sphere).
The anchor peptide is appended with an azide and incubated with the protein
and an OBOC library containing acetylene-functionalized peptides (secondary
screen). In situ triazole formation links the secondary peptide (red circles) to the
anchor to form the biligand. The biligand is then appended with an azide and
incubated with the acetylene-containing OBOC library to direct triazole
formation between the tertiary peptide (blue circles) and the biligand to form the
triligand (tertiary screen).
Fig. 2 Antibody/Fab Recognition of Protein Surfaces: using a subset of CDR loops. Binding of the protein antigen (yellow) to the antibody/Fab fragment (grey) is mediated by six
CDR loops, three from the light chain and three from the heavy chain. The CDR3 loops are shown in red and the CDR1 and CDR2 loops are shown in blue. (A) Lysozyme–antibody
complex (PDB code 1MLC).2 (B) HIVp24–Fab complex (1E6J).4 (C) VEGF–antibody complex (1BJ1).7 Protein structure images were generated in PyMol.
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through a novel quantitative PCR (QPCR)-based technique.
These experiments demonstrated the eﬃciency of the in situ
reaction was dependent on the target protein as well the orienta-
tion of the peptide ligands. The yield of the on-bead target-
catalyzed reaction was found to be approximately 1/1000th of the
copper-catalyzed process. Table 1 summarizes the screening
conditions and results of selected SISC and IPISC screens.
Analysis of IPISC screens; aﬃnity and
specificity
The improvement of ligand aﬃnity as a function of molecular
weight is a key metric for the eﬃciency of IPISC screens. To
quantify this, we have calculated the change in binding energy
(DDG) per additional heavy (nonhydrogen) atom as anchors are
translated to biligands and as biligands are translated to
triligands. This approach was originally described by Kuntz
and co-workers36 and later adapted by Hajduk to analyze the
eﬃciency of fragment-based drug discovery eﬀorts.37 We found
that the average change in binding energy for SISC screens was
approximately 0.2 kcal mol1 per heavy atom which is in
excellent agreement with previous studies (0.27 kcal mol1
per heavy atom).37 Similar analysis of the two IPISC screens
reveal an average change of approximately 0.03 kcal mol1 per
heavy atom, almost an order of magnitude lower than for SISC-
derived biligands. However, in the previous work mentioned
above, molecules in this size regime (>50 heavy atoms) are
Fig. 4 Structures of Triligand PCC Agents Obtained by IPISC. (a) Linear anti-bCAII triligand.3 (b) Branched anti-bCAII triligand (unpublished). (c) Anti-PSA triligand with
cyclic anchor peptide (unpublished). (d) Branched anti-Akt triligand.5
Table 1 Summary of SISC and IPISC screens
Target
[Target]
(nM) Screen d
Anchor KD
(nM)
Biligand KD
(nM)
Triligand KD
(nM)
DDG/Heavy atom
(kcal mol1 atom1)
NROT/kDa
(bonds/kDa) Ref.
AChE 1000 SISC 98 10–100 0.000077 n/a 0.25 18 14
AChE 1000 SISC 104 10–100 0.000100 n/a 0.20–0.25 17 45
AChE 1000 SISC 23 10–100 0.000033 n/a 0.29 21 46
bCAII 30 000 SISC 24 31–43 0.2–7.1 n/a 0.05–0.15 14–19 17
bCAII 10–50 IPISC 2  107 500 000 3000 45 0.037 (Biligand) 3
0.038 (Triligand) 37
HIV protease 15 000 SISC 5 3600–4800a 6a n/a 0.23 21 18
Chitinase B 9.6b SISC 71 536–624a 20–24a n/a 0.12 24 19
Akt1 9–110 IPISC 5.7  106 25 000 300 200 0.038 (Biligand) 5
0.003 (Triligand) 36
Target concentration denotes the concentration of target protein present in the screen. The parameter d is number of unique compounds present
in the combinatorial library from which the ligand components were selected. a Denotes an IC50 value.
b Denotes a concentration in mUnit per mL.
NROT/kDa is a measure of ligand conformational flexibility and denotes the number of rotatable bonds per kDa of molecular weight of the final
biligand or triligand. DDG/Heavy atom is a measure of the change in aﬃnity per addition of nonhydrogen atoms to the anchor ligand. This was
obtained by converting aﬃnity data for the ligands into DG (DG = RT ln KD) and dividing the change in DG by the change in nonhydrogen atom
composition. When unavailable, IC50 values were substituted for KD values without additional correction. For SISC screens the DDG/heavy atom of
the biligand was obtained relative to the anchor. For IPISC screens, the anchor was used as the reference compound for the biligand and the
biligand was used as the reference compound for the triligand.
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predicted to show almost no change in binding energy as the
molecular weight increases (DDG B 0.0002 kcal mol1 per
heavy atom). This suggests the possibility that peptide multi-
ligands are making additional energetic contacts with the
protein surface outside the anchor-binding site, resulting in
modest improvements in aﬃnity as size increases. This is in
contrast to SISC and other small molecule fragment-based
approaches where the energetic benefits of increasing the
molecular weight are essentially limited by the size and com-
position of the binding pocket.
The initial IPISC experiments suggest that screening for triligand
formation rather than target binding can lead to increased multi-
ligand specificity rather than aﬃnity. While the tertiary peptide in
the Akt triligand appears to contribute very little to the binding
energy for Akt, it partially destabilizes binding to GSK3b, the primary
oﬀ-target interaction.5 This is consistent with a pure product screen
which does not select for aﬃnity for the target, but rather compat-
ibility with target surface proximal to the anchor peptide binding
site. In this case, specificity can be achieved by excluding non-target
molecules whose surfaces are incompatible with one or more multi-
ligand components. This concept of ‘‘negative design’’ has been
exploited to design highly specific coiled-coil systems38 and a recent
study of SH3 domains demonstrates the significant gains in speci-
ficity from destabilizing oﬀ-target interactions.39 Previous work with
Herceptin, a therapeutic anti-Her2 antibody, demonstrated that the
specificity of two antibodies sharing common CDR3 loops (analo-
gous to anchor peptides in IPISC) can be dramatically altered by a
handful of mutations in the CDR-L1 loop.40 Here specificity is
controlled, in part, by what is excluded from the binding site. While
it is diﬃcult to draw broad conclusions from two screening experi-
ments, the product screen shows promise as a design tool for
improving ligand specificity without the need for complex and costly
counter-screening strategies.
Design of artificial receptors using in situ
click chemistry
The ligands obtained from the IPISC screens described above
target full-length folded proteins. However, a recent report from
Tanaka and co-workers describes the use of in situ click chemistry
to assemble an SH2 domain mimic which targets a short phos-
phorylated peptide.41 A resin-bound bis-lysine known to bind to
phosphate was employed as the anchor ligand and a phosphory-
lated cyclic peptide specific for the Grb2 SH2 domain was used as
the target. Two azides were appended to the anchor which could
form independent triazole linkages with members of an alkyne-
modified, solution phase, tetrapeptide library. In the presence of
the target cyclic peptide and low concentrations of copper catalyst,
the authors demonstrated that the each azide on the bis-lysine
anchor formed a triazole linkage with the same tetrapeptide
sequence. The resulting, branched structure bound to the Grb2-
specific phospho-peptide with lowmicromolar aﬃnity and showed
in vivo tumor volume reduction in C6-glioma mouse xenografts.
The use of copper to drive the reaction to completion suggests a
potential route to improving the yield of the reaction, albeit with a
corresponding increase in the background (non-templated) click
reaction. This approach diﬀers from IPISC screen notably in its use
of copper, rather than the protein target, to drive triazole for-
mation. In addition, it also utilizes an immobilized anchor ligand,
as well as a low diversity solution-phase library. However, the use
of target-guided click chemistry to assemble a branched peptide
further demonstrates that selectivemolecular recognition can arise
from the correct spatial orientation of short peptides.
Optimizing IPISC screening strategies
The Akt1 experiments demonstrated that the in situ click screen
was specific, but low yielding relative to the copper-catalyzed
process. While there is no explicit data for the product yield in
SISC screens, the observation of the product by liquid chroma-
tography indicates that the yield is significantly higher than the
peptide-based process where the on-bead product can only be
visualized after PCR-based amplification. The low concen-
tration of on-bead product leads to low signal-to-noise ratios
and selection of false positive hit beads. The yield of the on-bead
reaction is the most significant hurdle to the rapid and eﬃcient
design of ligands through Iterative Peptide In Situ Click Chemistry.
There are various explanations for this ineﬃciency, however we
will focus on the linkage between the IPISC ligand components
and the poor catalytic eﬃciency of the target protein.
The number of rotatable bonds (normalized for molecular
weight) in the final product is significantly higher in iterative
peptide screens than in small molecule screens (Table 1). This
arises from use of conformationally flexible component peptides
linked to each other through even more flexible hydrocarbon
chains. One potential consequence is a reduced probability of
azide and alkyne residing in the correct orientation necessary for
the in situ reaction to occur, resulting in a low observed yield of
triazole formation. A long, conformationally flexible linker would
also be predicted to prevent optimal energetic coupling between
the component peptides in the multiligand, lowering the aﬃnity
of the final product. This could be addressed in two ways, either
by reducing the length of the linkage between peptide compo-
nents or decreasing its conformational flexibility. The results from
the Akt1 study suggest that the IPISC screen selects for the best
peptide component in the context of the linker length used in the
screening experiment; arbitrarily shortening the linker was found
to significantly attenuate the aﬃnity of the designed biligand.5
The use of shorter linkers would also reduce the amount of
protein surface that can be sampled in an IPISC screen. Indeed,
a recent study by Mack and co-workers using a series of bivalent
bCAII inhibitors with long, flexible linkers demonstrated only
modest diﬀerences in binding aﬃnity to engineered bCAII
dimers, even when the linker lengths were significantly longer
than required (B2 kcal mol1 variation in binding energy over 40
Å of extended linker length).42 This observation suggests that long
linkers can be used to search for additional binding sites on the
protein surface while still retaining high aﬃnity in the multi-
ligand. Given the advantage of a long linker, it may be useful to
focus on increasing its conformational rigidity though introduc-
tion of non-rotatable bonds.
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The target protein also plays a critical role in the eﬃciency of the
in situ reaction. Ideally, the protein target will undergo multiple
turnover events and catalyze the formation of more than one
multiligand from the component ligands. However, if the protein
target templates the formation of a high aﬃnity multiligand, this
could lead to a very slow oﬀ rate (koﬀ) for the product, eﬀectively
preventing dissociation and rebinding of a new pair of component
ligands. This phenomenon has been observed in DNA-templated
synthesis due to the high-aﬃnity DNA duplexes that are formed
after covalent bond formation.43 A recent report by Sharma and co-
workers illustrates the high target concentrations required to drive
a low-turnover in situ click reaction to completion.44 In this study,
cocaine was used to template the ligation of two pieces of a cocaine-
binding split aptamer by in situ click chemistry. While the reported
yield was as high as 74%, this yield was obtained with a 500-fold
excess of cocaine. The low turnover of triazole product in in situ
click screens highlights the need for high concentrations of target
to generate adequate signal-to-noise ratios in IPISC screens. SISC
screens are generally carried out withmicromolar concentrations of
target and we have found that these concentrations result in more
eﬃcient product screens and fewer false-positive hits in IPISC.
Conclusions and future directions
As more potential protein biomarkers for disease are discovered,
the demand for compounds that can capture, detect, and inhibit
these proteins will commensurately increase. The IPISC design
process allows access to novel ligand architecture and composition,
opening the possibility for specific recognition of biomolecules that
are diﬃcult to target through traditional approaches. As demon-
strated by Tanaka and co-workers, branched peptides have enor-
mous potential to recognize phosphorylated peptide epitopes. The
IPISC design process can readily applied to other this and other
modifications including glycosylation, a post-translational modifi-
cation that has proven diﬃcult to target with high aﬃnity. Small
peptide epitope recognition, currently the province of antibodies
and their derivatives, represents another exciting application for
branched PCC Agents. Our groups are actively refining the IPISC
screening process to decrease the time from anchor to final
compound while concurrently improving the aﬃnity and specificity
of the ligand at each step. We envision these compounds finding
use as antibody alternatives in immunohistochemistry, probes for
molecular imaging, and novel therapeutics that couple the most
desirable properties of antibodies with the stability and economy of
synthetic compounds.
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